Relmada Therapeutics Inc. (RLMD) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Relmada Therapeutics Inc. (NASDAQ: RLMD) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $3.84 (+7.26% 1D, market cap $381.9M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RLMD carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, RZLT (Rezolute Inc. (NV)) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $382.1M) and AVTX (Avalo Therapeutics Inc.) posts a E grade (17/100 RQD, P/E N/A, ROIC -35.0%, cap $384.5M). Among the 5-stock peer group, RLMD leads on earnings multiple (N/A) while ALT leads on capital efficiency (-34.7% ROIC).
Per RLMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001553643), Relmada Therapeutics Inc. generated $165.5M in revenue (-29.6% YoY), $0 in net income, and -$45.8M in free cash flow against $94.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While RLMD currently carries a cautious 30/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.80) and Max Pain ($4.03) forces dealer call-delta covering toward $8.40.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Relmada Therapeutics Inc. (RLMD) surged +7.26% to $3.84, trading at 29% of its 52-week range ($2.15 – $8). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo! Finance Canada report covering Relmada Therapeutics Inc. (RLMD) market action, institutional positioning, and fundamental catalysts.
Moomoo report covering Relmada Therapeutics Inc. (RLMD) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Relmada Therapeutics Inc. (RLMD) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Relmada Therapeutics Inc. (RLMD) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Relmada Therapeutics Inc. (RLMD) market action, institutional positioning, and fundamental catalysts.
TradingKey report covering Relmada Therapeutics Inc. (RLMD) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Relmada Therapeutics Inc. (RLMD) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Relmada Therapeutics Inc. (RLMD) market action, institutional positioning, and fundamental catalysts.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on RLMD today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for RLMD. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Relmada Therapeutics Inc. (RLMD) ranks #795 by composite RQD confidence (30/100, grade E) and #482 by equity capitalization ($381.9M). Within this direct 5-issuer industry benchmark cohort, RLMD leads on earnings valuation at N/A trailing P/E, while ALT leads on capital efficiency and profitability with -34.7% ROIC and — gross margin. RZLT currently holds the highest overall quantitative score in the immediate peer group at 37/100 (D-) compared with RLMD at 30/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| RLMD
ACTIVE
Relmada Therapeutics Inc. | E | 30/100 | — | — | -35.0% | +7.26% | $381.9M | Benchmark Subject |
| RZLT Rezolute Inc. (NV) | D- | 37/100 | — | — | -35.0% | -1.77% | $382.1M | /rzlt-vs-rlmd → |
| AVTX Avalo Therapeutics Inc. | E | 17/100 | — | — | -35.0% | +2.09% | $384.5M | /avtx-vs-rlmd → |
| CAPR Capricor Therapeutics Inc. | E | 34/100 | — | — | -35.0% | +13.48% | $370.9M | /capr-vs-rlmd → |
| ALT Altimmune Inc. | E | 21/100 | — | — | -34.7% | -0.98% | $396.8M | /alt-vs-rlmd → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Relmada Therapeutics Inc. (RLMD) reported GAAP revenue of $165.5M (-29.6% vs. FY2024 revenue of $234.9M ) , GAAP net income of $0, operating cash flow of -$45.8M, and free cash flow of -$45.8M (+11.5% YoY). On the balance sheet, RLMD closed FY2025 with $94.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $165.5M | $0 | -$45.8M | -$45.8M | $94.0M | — |
| FY2024 (FY) | 2024-12-31 | $234.9M | $0 | -$51.8M | -$51.8M | $45.8M | — |
As of 2026-11-03, Relmada Therapeutics Inc. (NASDAQ: RLMD) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $3.84 (+7.26% 1D, market cap $381.9M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RLMD carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, RZLT (Rezolute Inc. (NV)) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $382.1M) and AVTX (Avalo Therapeutics Inc.) posts a E grade (17/100 RQD, P/E N/A, ROIC -35.0%, cap $384.5M). Among the 5-stock peer group, RLMD leads on earnings multiple (N/A) while ALT leads on capital efficiency (-34.7% ROIC).
Per RLMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001553643), Relmada Therapeutics Inc. generated $165.5M in revenue (-29.6% YoY), $0 in net income, and -$45.8M in free cash flow against $94.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
RLMD last traded at $3.84 (+7.26% on volume of 2,257,005 shares), positioning the stock +1.05% above its 50-day simple moving average ($3.80) and -28.22% below its 200-day simple moving average ($5.35). Across its 52-week range of $2.15 to $8.00, RLMD sits at the 28.9% percentile with a 14-day RSI of 52.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.36 to $4.32).
Relmada Therapeutics Inc. (RLMD) earns a live Roarable RQD composite score of 30/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $3.84 (+7.26% 1D, market capitalization $381.9M).
Relmada Therapeutics Inc. Is a NASDAQ-listed issuer classified in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry..4B. Reported revenue is — for both FY 2025 and FY 2024 in the SEC financials, indicating no revenue recognition in the reported periods.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Relmada Therapeutics Inc. (RLMD) reported $165.5M in annual revenue (up from $234.9M in FY2024, -29.6% YoY) and $0 in GAAP net income. Over the multi-year SEC filing window from FY2024 ($234.9M revenue, $0 net income) through FY2025, RLMD scaled operating cash flow to -$45.8M and free cash flow to -$45.8M, backed by $94.0M in total assets against $0 in total debt.
The only cross-market linkage is the macro liquidity signal, which implies the stock's sensitivity to broad liquidity conditions rather than to any specific supplier or customer. Because the graph shows a high beta elasticity to net liquidity, a prospective investor should note that liquidity-driven moves could amplify price changes in either direction.
Real-time company headlines, analyst actions, and sector developments for Relmada Therapeutics Inc. (RLMD) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo! Finance Canada report covering Relmada Therapeutics Inc. (RLMD) market action, institutional positioning, and fundamental catalysts.
Moomoo report covering Relmada Therapeutics Inc. (RLMD) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Relmada Therapeutics Inc. (RLMD) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Relmada Therapeutics Inc. (RLMD) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Relmada Therapeutics Inc. (RLMD) market action, institutional positioning, and fundamental catalysts.
TradingKey report covering Relmada Therapeutics Inc. (RLMD) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Relmada Therapeutics Inc. (RLMD) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Relmada Therapeutics Inc. (RLMD) market action, institutional positioning, and fundamental catalysts.
Picked up a starter position in RLMD in my $100K Virtual Cash book at $3.58. The Butterfly Supply-Chain Graph's LIQUIDITY_TAILWIND signal scores 96/100 and is marked BULLISH, indicating a macro backdrop that favors the stock despite falling net liquidity.. Trading inside a $2.15–$8.00 52-week range with -12.48% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.
Both sides have a point here — RLMD's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
Here is the bear case nobody on the bull side wants to address on RLMD: Negative free cash flow of -$45.8M against only $3.5M in cash, a Piotroski F-Score of 1/9, and an RQD grade of E all point to significant forensic and funding risk.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).